LR Health & Beauty SE Reports Q3 2025 Business Development

LR Health & Beauty SE released preliminary figures for Q3 2025, reflecting sales of EUR 66.0 million, marking a 5% decline from Q3 2024. Over the first nine months, sales reached EUR 208.8 million, down 1.8% from the previous year. The company's EBITDA fell to EUR 2.9 million in Q3 2025, a noticeable 59.9% drop compared to the previous year.

LR launched successful new collections in its fragrance segment, aiming to improve sales and expand market opportunities for distributors. Despite challenging market conditions and consumer sentiment, new product launches provided positive momentum. LR is focusing on enhancing its capital and financing structure, while revising its 2025 sales and earnings guidance.

The company now anticipates 2025 sales to range between EUR 276 million and EUR 281 million, with EBITDA between EUR 17 million and EUR 20 million. LR continues discussions with bond creditors and is developing a restructuring plan to bolster financial sustainability.